anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Disorders of serum sodium are common among general patients and are associated with poor outcomes. The prognostic value of serum sodium disorders in patients with acute pancreatitis (AP) has not been studied. We conducted this retrospective study to explore the association between serum sodium levels and the outcomes of patients with AP.
MATERIALS AND METHODS: Patients with AP from the Medical Information Mart for Intensive Care III (MIMIC-III) were screened for this study. The laboratory variables, including serum sodium levels, were obtained by analyzing the first blood sample on the first day after admission. Univariate logistic regression was performed to discover potential factors for mortality of AP. The unadjusted and adjusted association between serum sodium level and mortality of AP was shown by the restricted cubic spline (RCS). The categorical cutoff for the detrimental effect of serum sodium level on the prognosis of AP was also confirmed by stepwise logistic regression after adjusting for con-founding effects of significant factors in the univariate logistic regression.
RESULTS: A total of 869 patients with AP in the MIMIC-III were included with a mortality of 13.1%. Unadjusted logistic regression showed that age (p < 0.001), simplified acute physiological score (SAPS) (p < 0.001), systolic blood pressure (p < 0.001), diastolic blood pressure (p < 0.001), hemoglobin (p = 0.040), serum creatinine (p = 0.046), and serum phosphorus (p < 0.001) were significantly associated with the mortality of AP. The RCS showed that the serum sodium level was negatively and linearly associated with mortality of AP after adjusting for confounding effects of significant factors in the univariate logistic regression. Serum sodium < 133 mmol/L, which indicated hyponatremia, was significantly correlated with a higher mortality risk than serum sodium ≥ 133 mmol/L (p = 0.013).
CONCLUSIONS: Hyponatremia is widely developed among patients with AP and correlates with a higher mortality risk of AP. Physicians should pay more attention to managing patients with AP with hyponatremia.
A polyol gel is made from 15-62 wt. % (based on the sum of polyurethane matrix plus dispersing agent) of a high molecular weight covalently cross-linked polyurethane matrix; 85-38 wt. % (based on the sum of polyurethane matrix plus dispersing agent) of a liquid dispersing agent which is firmly bonded to the matrix; and optionally, active ingredients, fillers, additives, catalysts, and mixtures thereof. The liquid dispersing agent is a polyhydroxyl compound having a molecular weight of between 1,000 and 12,000 and an OH number between 20 and 112. This dispersing agent should have virtually no hydroxyl compounds having a molecular weight below 800 present. These gel compositions may be used to make mold impressions and highly stable active-ingredient releasing compositions.
SOX proteins are transcription factors which play a role in regulating the development of progenitor cells and tissue differentiation. Twenty members are known, clustered in eight groups named A through H and sharing a common DNA-binding domain called the HMG (high-mobility-group) box. Eleven of the SOX genes have been associated with genetic disorders so far, covering a broad spectrum of developmental diseases. SOX4 is a single-exon gene and belongs to the SOXC group, together with SOX11 and SOX12. SOX4 variants have been recently described to cause a highly penetrant but heterogeneous disorder, with a phenotypic spectrum ranging from mild developmental delays and learning difficulties to intellectual disabilities with congenital anomalies. Nineteen pathogenic variants have been reported to date, generally de novo, heterozygous, and inactivating, either stop-gain or missense, the latter ones primarily targeting the HMG domain. Further, a bi-allelic variant was reported in a single consanguineous family. Copy number variants leading to whole gene deletion or duplication are rare and not clearly associated with any neurodevelopmental disorder. Many open questions remain regarding the definition of variants of unknown significance, a possible role of missense variants outside the HMG domain, genotype-phenotype correlation, the range of phenotypic spectrum and modifying factors, and treatment options.
All YLWH who choose to enroll in the study will receive access to AiCure, the mobile health application. The participants will be asked to use the app for 3 months, during which the investigators will assess the feasibility and acceptability of AiCure.
Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Continuous medication for more than 3 months per year, or intermittent medication for more than 6 months per year was the exposure group (TCM diagnosis and treatment plan cohort).
The participants in the experimental group were divided into five groups of eight participants each according to the number of days they visited the center. The training was conducted face to face in the meeting room of the special education and rehabilitation center. Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks . The duration of each training session was 60-90 minutes. The weekly training sessions for all the experimental groups were completed on the same day.
INTRODUCTION: Prolonged operation of construction equipment could lead to mental fatigue, which can increase the chances of human error-related accidents as well as operators' ill-health. The objective detection of operators' mental fatigue is crucial for reducing accident risk and ensuring operator health. Electroencephalography, photoplethysmography, electrodermal activity, and eye-tracking technology have been used to mitigate this issue. These technologies are invasive and wearable sensors that can cause irritation and discomfort. Geometric measurements of facial features can serve as a noninvasive alternative approach. Its application in detecting mental fatigue of construction equipment operators has not been reported in the literature. Although the application of facial features has been widespread in other domains, such as drivers and other occupation scenarios, their ecological validity for construction excavator operators remains a knowledge gap.
METHOD: This study proposed employing geometric measurements of facial features to detect mental fatigue in construction equipment operators' facial features. In this study, seventeen operators performed excavation operations. Mental fatigue was labeled subjectively and objectively using NASA-TLX scores and EDA values. Based on geometric measurements, facial features (eyebrow, mouth outer, mouth corners, head motion, eye area, and face area) were extracted.
RESULTS: The results showed that there was significant difference in the measured metrics for high fatigue compared to low fatigue. Specifically, the most noteworthy variation was for the eye and face area metrics, with mean differences of 45.88% and 26.9%, respectively.
CONCLUSIONS: The findings showed that geometrical measurements of facial features are a useful, noninvasive approach for detecting the mental fatigue of construction equipment operators.
PURPOSE: We aimed at assessing the predictive ability of ultrasound-based radiomics combined with clinical characteristics for axillary lymph node (ALN) status in early-stage breast cancer patients and to compare performance in different peritumoral regions.
MATERIALS AND METHODS: A total of 755 patients (527 in the primary cohort and 228 in the external validation cohort) were enrolled in this study. Ultrasound images for all patients were acquired and radiomics analysis performed for intratumoral and different peritumoral regions. The MRMR and LASSO regression analyses were performed on extracted features from the primary cohort to construct a radiomics signature formula combined with clinical characteristics. Pearson's coefficient and the variance inflation factor (VIF) were performed to check the correlation and the multicollinearity among the final predictors. The best performing model was selected to develop a nomogram, which was established by performing binary logistic regression and acquiring cut-off values based on the corresponding nomogram scores of the masses.
RESULTS: Among all the radiomics models, the "Mass + Margin3mm" model exhibited the best performance. The areas under the curves (AUC) of the nomogram in the primary and external validation cohorts were 0.906 (95% confidence intervals [CI] 0.882-0.930) and 0.922 (95% CI 0.894-0.960), respectively. They both showed good calibrations. The nomogram exhibited a good ability to discriminate between positive and negative lymph nodes (AUC: 0.853 (95% CI 0.816-0.889) in primary cohort, 0.870 (95% CI 0.818-0.922) in validation cohort), and between low-volume and high-volume lymph nodes (AUC: 0.832 (95% CI 0.781-0.884) in primary cohort, 0.911 (95% CI 0.858-0.964) in validation cohort).
CONCLUSIONS: The established nomogram is a prospective clinical prediction tool for non-invasive assessment of ALN status. It has the ability to enhance the accuracy of early-stage breast cancer treatment.
PURPOSE: Provided is an apoptosis inducer which consists of arsenic hexaoxide(As4O6) capable of treating various blood cancers including leukemia and solid cancer. CONSTITUTION: The apoptosis inducer of the formula consists of arsenic hexaoxide(As4O6). The apoptosis inducer induces an apoptosis by generating active oxygen. The apoptosis is useful to prevent and treat various diseases associated with apoptosis mechanism. Also, the arsenic hexaoxide effectively induce an apoptosis in U937 leukemia cell line which is known to have a resistance to arsenic trioxide, even in low concentration. Therefore, the arsenic hexaoxide can be broadly applied to various blood cancers including leukemia, as well as various solid cancers.
An emulsion component includes a polyglycerol ester-base emulsifier and a polyglycerol ester-based coemulsifier. The polyglycerol ester-base emulsifier has a hydrophilic-lipophilic balance value greater than 10, and is formed by reacting a first polyglycerol having a degree of polymerization ranging from 4 to 20 with a first acid. The polyglycerol ester-based coemulsifier has a hydrophilic-lipophilic balance value not greater than 10, and is formed by reacting a polyol with a second acid. The polyol is selected from the group consisting of a glycerol and a second polyglycerol having a degree of polymerization ranging from 2 to 10. In addition, a weight ratio of the polyglycerol ester-based emulsifier and the polyglycerol ester-based coemulsifier ranges from 0.75 to 8. An oil-in-water sunscreen product including the emulsion component and an oil-in-water sunscreen lotion including the emulsion component are also provided.
An energy balancing system scales portion sizes of user-selected meal recipes to control a digital scale to prompt the user to measure scaled quantities of meal ingredients to prepare scaled meals. Physical activity tracking devices provide data to generate physical activity energy expenditures for energy burned by physical activity. The physical activity energy is added to a basal metabolic rate of energy expenditure that is a function of sex, weight, height, and age. The total energy expended are scaled down for a weight-loss goal to obtain the total recommended energy. A recipe portion-size optimizer adjusts scaling factors for each recipe so that the total recommended energy is met by the scaled meals. Amounts of nutrients for the recipes can also be scaled by the scaling factors to match recommended nutrient amounts when the meal recipe optimizer generates the scaling factors using an over-determined linear system optimizer.
According to various aspects of the present application, embodiments of an infusion pump for administering medication to a patient are provided. According to one embodiment, the infusion pump automatically determines time intervals and associated rates of infusion of the medication, and automatically controls a pump engine to infuse the medication for the determined time intervals at the associated rates of infusion. According to another embodiment, the infusion pump determines whether an infusion set is configured to infuse medication into a patient at one site or at two sites. The infusion pump then controls the pump engine based on the determined configuration of the infusion set. According to another embodiment, the infusion pump automatically primes the infusion set for infusion of medication into a patient. According to another embodiment, the infusion pump automatically determines whether one or more needles have been placed on the patient correctly.
OBJECTIVES: Patients with metastatic prostate cancer (mPCa) with BReast CAncer gene (BRCA) mutations benefit from targeted treatments (eg, olaparib). In addition, family members of affected patients have increased risk of hereditary cancers and benefit from early detection and prevention. International guidelines recommend genetic testing in mPCa; however, the value for money of testing patients with mPCa and cascade testing of blood-related family members has not been assessed. In this context, we evaluated the cost-effectiveness of germline BRCA testing in patients with mPCa followed by cascade testing of first-degree relatives (FDRs) of mutation carriers.
METHODS: We conducted a cost-utility analysis of germline BRCA testing using 2 scenarios: (1) testing patients with mPCa only and (2) testing patients with mPCa and FDRs of those who test positive. A semi-Markov multi-health-state transition model was constructed using a lifetime time horizon. The analyses were performed from an Australian payer perspective. Decision uncertainty was characterized using probabilistic analyses.
RESULTS: Compared with no testing, BRCA testing in mPCa was associated with an incremental cost of AU$3731 and a gain of 0.014 quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio of AU$265 942/QALY. Extending testing to FDRs of variant-positive patients resulted in an incremental cost-effectiveness ratio of AU$16 392/QALY. Probability of cost-effectiveness at a willingness-to-pay of AU$75 000/QALY was 0% in the standalone mPCa analysis and 100% in the cascade testing analysis.
CONCLUSION: BRCA testing when performed as a standalone strategy in patients with mPCa may not be cost-effective but demonstrates significant value for money after the inclusion of cascade testing of FDRs of mutation carriers.
PACU and ward providers caring for participants in the full contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.
Background: Biotin-thiamine-responsive basal ganglia disease (BTBGD) is a rare, treatable autosomal recessive neurometabolic disorder. This condition eventually leads to severe disability and death if not treated correctly. The clinical features of BTBGD, especially those with unusual complications, are not widely known by neurologists or pediatricians.Case presentation: A 4-month-old male infant was admitted to the hospital with a history of cough for the past 7 days and convulsions of 6 h duration. Physical examination showed confusion, bilateral pupillary light reflex delays, hypertonia of limbs, and brisk tendon reflexes of the limbs. Brain magnetic resonance imaging (MRI) showed multiple abnormal signals in the bilateral basal ganglia, lobes, corpus callosum, brainstem, and brain atrophy. However, his condition continued to worsen. Computed tomography performed 3 months later showed severe subdural hematoma and effusion. Subsequently, he underwent puncture drainage; however, his condition did not improve postoperatively. Repeated MRIs showed increasing subdural hematoma and effusion, and brain atrophy. The patient was diagnosed with BTBGD following whole-genome sequencing, which identified a novel compound heterozygous mutation of SLC19A3 gene. He was treated with biotin and thiamine, and the symptoms gradually improved. Subsequent MRIs showed a decrease in the subdural hematoma and effusion and partial improvement in brain atrophy.Conclusion: To the best of our knowledge, this is the first reported case of BTBGD, complicated by severe subdural hematoma. These observations extend our understanding of the clinical features, neuroimaging spectrum, and gene mutation spectrum of BTBGD. The phenotypic spectrum and pathophysiology of BTBGD are not completely understood and need to be studied further.
The CROWN CORONATION trial will randomly allocate adult participants to a single intramuscular injection of MMR vaccine or Placebo (0.9% saline). All participants in this sub-study receive SARS-CoV-2 specific vaccine subsequent to the MMR or Placebo injection.
The invention discloses a schistosoma japonica enolase gene and a coding protein and an application thereof. The schistosoma japonica enolase gene comprises nucleotide sequences shown by SEQ ID No. 1-SEQ ID No. 3; and schistosoma japonica enolase comprises a protein with nucleotide sequences shown by SEQ ID No. 4-SEQ ID No. 6 or a protein with the same function formed by replacing and deleting or inserting the protein. In addition, the invention also discloses a schistosoma japonica enolase gene and an application of a coding protein thereof. The schistosoma japonica enolase can be applied to schistosome vaccine preparation, medicament screening, anti-schistosoma antibody preparation and serodiagnosis; and the schistosoma japonica superoxide dismutase gene can be applied to gene therapy.
Asymptomatic carotid stenosis (ACS) carries a 4.7% risk of ipsilateral stroke if left untreated. Carotid endarterectomy (CEA) is a surgical intervention that has demonstrated efficacy in reducing stroke risk among symptomatic elderly. However, literature on its efficacy in preventing stroke in patients with ACS remains limited. Our systematic review summarizes evidence on the safety and efficacy of CEA in the asymptomatic elderly.PubMed and Scopus were searched to identify articles that described outcomes after CEA for ACS in patients aged ≥ 65 years old. Articles that did not report outcomes specific to the asymptomatic elderly were excluded. Outcomes of interest were technical success, stroke, death, myocardial infarction and post-operative complications. The Newcastle Ottawa Scale (NOS) was used to perform a qualitative assessment for risk of bias and studies with NOS ≥ 6 were considered high quality. This systematic review was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement.After a title and abstract screen, followed by a full-text review, 7 studies reporting outcomes in 76,404 patients were included. Five studies were retrospective and two were prospective. Among studies that reported criteria for intervention in ACS patients, 2 studies performed CEA for 70% stenosis and one performed CEA for 60% stenosis. One study reported outcomes for all ranges of stenosis (mild: 0-50%, moderate: 50-79% and severe: 80-99%). Clinical outcomes varied among included studies, with rates of death stroke and myocardial infarction ranging from 0.39 to 6.1%, 0.5-1.2% and 0.9-3%, respectively.The decision to perform CEA in patients with ACS is made after outweighing risks and benefits of surgery based on various factors like age, comorbidities and frailty. At present, evidence is largely limited to retrospective studies that utilized nationwide databases. Prospective studies and randomized controlled trials could help characterize the risk of CEA in this cohort.
Dextrose Injection 5%, USP is a clear, sterile solutions of dextrose supplied in single-dose, partial-fill flexible containers. 

Do not remove container from the overwrap until intended for use.

Use the product immediately after mixing and the introduction of additives.

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C/77°F).
Kinases are known to have kinase activity independent functions. To gain further insights into potential kinase-independent functions of SLK/STK2, we have developed a kinase-dead allele, SLKK63R using in vivo CRISPR/Cas technology. Our studies show that blastocysts homozygote for SLKK63R do not develop into viable mice. However, heterozygotes are viable and fertile with no overt phenotypes. Analyses of mouse embryonic fibroblasts show that expression of SLKK63R results in a 50% decrease in kinase activity in heterozygotes. In contrast to previous studies, our data show that SLK does not form homodimers and that the kinase defective allele does not act in a dominant negative fashion. Expression of SLKK63R leads to altered Rac1 and RhoA activity, increased stress fiber formation and delayed focal adhesion turnover. Our data support a previously observed role for SLK in cell migration and suggest that at least 50% kinase activity is sufficient for embryonic development.
Symptom management is essential in home caregiving. However, many informal caregivers are not confident of their ability to assist their their loved ones with their cancer symptoms at home. A low level of confidence or self-efficacy may negatively affect a caregiver's psychological well-being which is already vulnerable as a consequence of caregiving. Because of the reciprocal nature in a caregiver-patient dyad, caregiver decline is likely associated with patient decline. Improving caregivers' self-efficacy to manage their loved ones' cancer-related symptoms may mitigate their psychological decline and may positively affect patients' well-being by alleviating their symptom distress. Additionally, training in self-management of stress may promote coping among caregivers as many data show that caregiver stress is overwhelming.

This study will examine the effects of an Enhanced Caregiver Training protocol delivered to informal caregivers of cancer patients before hospital discharge. The primary aim is to test the effects of the training on caregivers' self-efficacy in cancer symptom management and self-efficacy in self-management of stress. The study will also look at the effects of this training on caregiver outcomes (depression, anxiety, quality of life, caregiver stress) and patient outcomes (symptom distress and intensity, depression, anxiety, quality of life). The study will use a treatment and attention-control group. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress, whereas subjects in the attention-control group will receive an informational session about cancer and resources for caregiving. Data will be collected before and after the training, and at 2 and 4 weeks after hospital discharge. Descriptive statistics and multivariate analysis including mixed models will be used for data analysis This study could have important implications for the nursing community on how to effectively prepare informal cancer caregivers for home caregiving prior to hospital discharge. The long term goal is to refine and expand the training so that it can be used to teach and support informal caregivers of patients suffering from other chronic illnesses, and to determine the cost-effectiveness of this training.